Liraglutide is the GLP-1 drug that came before semaglutide, and it is the one that proved the whole category could work for weight loss.
GLP-1 is a hormone your gut releases after eating. It prompts insulin release, slows stomach emptying, and signals fullness to the brain. Liraglutide is a modified version that resists the enzyme that would normally break the natural hormone down within minutes, stretching its life to around 13 hours.
That is the main practical difference from what replaced it. Thirteen hours means a daily injection, while semaglutide lasts long enough for weekly dosing. Convenience is a large part of why liraglutide has been overshadowed.
It is sold as Victoza for type 2 diabetes and Saxenda for weight management, both approved by the FDA. Generic liraglutide is now available, which makes it one of the few GLP-1 options with a genuine low cost route.
For educational and research purposes only. Never use any peptide or substance based on information found here — always consult a licensed healthcare professional before making any medical or health-related decision.
No reviews yet. Be the first.
AOD9604 is a fragment of human growth hormone — specifically the last 15 amino acids at one end of the molecul…
Cagrilintide is a long acting version of amylin, a hormone your pancreas releases alongside insulin whenever y…
CJC-1295 is a synthetic version of a hormone your body already produces called GHRH — growth hormone releasing…
Liraglutide has something almost nothing else in the peptide world has: years of approved use in millions of people, with the safety and effectiveness record that comes from it.
The trial program behind approval showed consistent, clinically meaningful weight loss at the 3.0 mg dose, and real world follow up has matched it. One clinical evaluation in patients awaiting bariatric surgery found an average reduction of 10.9 kg at 26 weeks and 14 kg at 52 weeks, with 86 percent losing at least 5 percent of body weight.
It also has cardiovascular outcome data in type 2 diabetes, meaning it was tested not just for weight and blood sugar but for whether it reduced heart attacks and strokes. Very few weight loss treatments have ever been held to that standard.
Its limitation compared with newer drugs is straightforward. Semaglutide and tirzepatide produce more weight loss with less frequent injections. Liraglutide is the older, weaker, more inconvenient option, and it is also the cheapest and the best understood.